1 Introduction

Lung cancer remains one of the most common and deadliest forms of cancer worldwide, with non-small cell lung cancer (NSCLC) being the predominant subtype. It is a leading cause of cancer-related mortality globally, and despite advancements in medical treatment, it still poses significant challenges. Radiotherapy plays a pivotal role in the treatment of lung cancer, particularly for patients with inoperable tumors, those in advanced stages, or those who refuse surgery. It is utilized for both curative and palliative purposes across all stages of the disease, significantly contributing to survival and quality of life improvements (Vinod and Hau, 2020).

Conventional radiotherapy techniques have limitations, primarily due to their inability to precisely target tumors while sparing healthy tissue. This results in significant side effects such as radiation-induced damage to surrounding organs like the lungs and heart, leading to complications such as pneumonitis, cardiac disease, and other radiation toxicities. Additionally, local control of the disease is often inadequate in advanced-stage lung cancer, and survival rates remain suboptimal despite treatment (Ball et al., 2019). Other challenges include tumor heterogeneity and intrinsic resistance to radiotherapy, which contribute to relapse and metastasis.

The current research explores innovations in radiotherapy techniques and their clinical applications to overcome the limitations of traditional methods. These innovative techniques include stereotactic body radiotherapy (SBRT), intensity-modulated radiotherapy (IMRT), and proton beam therapy (PBT), which hold the potential to improve tumor targeting, reduce toxicity, and enhance local control and survival rates. By integrating advanced imaging technologies, artificial intelligence, and personalized treatment approaches, the precision and effectiveness of radiotherapy can be increased, ultimately improving treatment outcomes for lung cancer patients (Fiorino et al., 2020).

The primary objective of this study is to explore and evaluate innovations in radiotherapy, particularly how to overcome the limitations of conventional radiotherapy in the treatment of lung cancer. Traditional radiotherapy methods have limitations in terms of targeting precision and minimizing damage to healthy tissues, resulting in significant side effects and suboptimal survival rates. By introducing advanced techniques such as stereotactic body radiotherapy (SBRT), intensity-modulated radiotherapy (IMRT), and proton beam therapy (PBT), this study aims to achieve more precise tumor targeting while reducing radiation toxicity, thereby improving local control and survival rates. Additionally, the integration of advanced imaging technologies, artificial intelligence, and personalized treatment approaches further enhances the precision and effectiveness of radiotherapy, with the ultimate goal of improving treatment outcomes for lung cancer patients. This study holds theoretical significance, providing a foundation for the future development of radiotherapy for lung cancer, and it also has important clinical implications, offering optimized treatment strategies to improve overall prognosis for lung cancer patients.

2 Advances in Radiotherapy Techniques for Lung Cancer

2.1 Stereotactic body radiotherapy (SBRT)

Stereotactic body radiotherapy (SBRT) has revolutionized the treatment of early-stage non-small cell lung cancer (NSCLC), particularly for medically inoperable patients. This technique delivers highly focused, high-dose radiation to tumor sites while minimizing exposure to surrounding healthy tissues. SBRT's precise targeting has significantly improved local control rates and reduced treatment-related toxicities, making it an attractive option for early-stage lung cancer patients. Recent studies have shown that SBRT offers comparable outcomes to surgery, especially in elderly patients or those with comorbidities (Diwanji et al., 2017). SBRT also offers a non-invasive alternative to patients who are unfit for surgery, demonstrating excellent control of local tumors with a favorable toxicity profile (Kreinbrink et al., 2017).

2.2 Intensity-modulated radiotherapy (IMRT)

Intensity-modulated radiotherapy (IMRT) is an advanced radiotherapy technique that allows for the precise modulation of radiation beams to conform to the shape of the tumor. This results in higher radiation doses to the tumor while sparing adjacent normal tissues, such as the lungs and heart. IMRT has demonstrated efficacy in treating both early-stage and locally advanced NSCLC by reducing the risk of radiation-induced toxicities while maintaining high local control rates. Furthermore, IMRT is particularly beneficial for patients with complex tumor geometries or those with tumors near critical structures like the heart and spine (Diwanji et al., 2017). Recent innovations, such as volumetric-modulated arc therapy (VMAT), have further enhanced the precision and delivery speed of IMRT, making it a cornerstone in modern radiotherapy for lung cancer.

2.3 Proton and heavy ion therapy

Proton therapy, with its unique Bragg peak phenomenon, delivers radiation more precisely to the tumor while minimizing damage to surrounding tissues. This makes it an ideal choice for treating lung cancers located near critical structures, such as the heart and spinal cord. Proton therapy has shown promise in reducing radiation-induced side effects, particularly in patients with locally advanced NSCLC. Furthermore, advanced techniques like pencil beam scanning (PBS) have enhanced the precision of proton therapy, allowing for better dose distribution in complex tumors (Harada and Murayama, 2017). In addition to proton therapy, heavy ion therapy, specifically carbon-ion therapy, offers superior biological effectiveness due to its enhanced ability to kill cancer cells regardless of their oxygen levels or cell cycle phase. Carbon-ion therapy has shown potential for treating radioresistant lung tumors and is under active investigation in clinical trials (Shioyama et al., 2017).

3 Clinical Evidence Supporting Innovative Radiotherapy Approaches

3.1 SBRT in early-stage lung cancer

Stereotactic body radiotherapy (SBRT) has demonstrated excellent clinical outcomes in the treatment of early-stage non-small cell lung cancer (NSCLC), particularly for patients who are medically inoperable. Clinical studies show that SBRT achieves high rates of local control, with 5-year local control rates reaching up to 90% (Bae et al., 2022). SBRT has also been shown to offer comparable survival outcomes to surgery, with minimal treatment-related toxicity, making it a standard of care for early-stage, medically inoperable patients (Sun et al., 2020). Additionally, the use of SBRT in elderly patients has been found to be particularly safe and effective, with reduced rates of severe toxicity even in high-risk populations (Cassidy, 2017).

3.2 IMRT for locally advanced lung cancer

Intensity-modulated radiotherapy (IMRT) has become the standard radiotherapy approach for locally advanced NSCLC, offering superior precision by modulating radiation doses to conform to the tumor’s shape. This allows for effective tumor targeting while minimizing radiation exposure to surrounding healthy tissues such as the heart and lungs. Clinical evidence from the NRG Oncology RTOG 0617 trial supports the use of IMRT, showing a reduction in severe radiation-induced pneumonitis and cardiac toxicity compared to older techniques like 3D-CRT (Chun et al., 2017). IMRT also enables better sparing of critical organs, leading to improved patient outcomes without compromising survival rates.

3.3 Proton therapy in lung cancer

Proton therapy offers significant dosimetric advantages over photon-based therapies due to the unique properties of the proton beam, which deposits its dose in the tumor while minimizing exposure to surrounding healthy tissues. Clinical studies indicate that proton therapy is especially beneficial for treating lung cancer near sensitive structures, such as the heart and lungs, where it reduces the risk of radiation-induced toxicities. In patients with locally advanced NSCLC, proton therapy has been shown to lower the risk of pneumonitis and cardiac complications compared to IMRT, while maintaining similar survival rates (Harada and Murayama, 2017). Furthermore, studies highlight that proton therapy can achieve excellent local control rates and reduce toxicity even in high-risk patients with large tumors or poor lung function (Wang, 2024a).

4 Integration of Radiotherapy with Systemic Therapies

4.1 Combining radiotherapy with chemotherapy

Radiotherapy combined with chemotherapy has long been a standard treatment for non-small cell lung cancer (NSCLC), especially in locally advanced stages. Chemotherapy, typically used concurrently with radiotherapy, sensitizes cancer cells to radiation, enhancing the efficacy of the treatment. This combination has been shown to improve overall survival and progression-free survival when compared to radiotherapy alone (Muto et al., 2020). However, combining radiotherapy and chemotherapy can increase the risk of treatment-related toxicity, particularly in normal tissues such as the lungs and esophagus (Sacco et al., 2017).

4.2 Radiotherapy and immunotherapy combinations

In recent years, the combination of radiotherapy with immunotherapy has garnered significant attention, especially with the advent of immune checkpoint inhibitors like PD-1/PD-L1 inhibitors. Radiotherapy is thought to stimulate the immune system by inducing immunogenic cell death and increasing tumor antigen presentation, which enhances the efficacy of immunotherapy (Wirsdörfer et al., 2018). This combination has led to the observation of the "abscopal effect," where tumors outside the radiation field also respond to treatment, potentially mediated by immune activation (Bhalla et al., 2018). Trials such as the PACIFIC trial demonstrated the survival benefits of combining chemoradiotherapy with immune checkpoint inhibitors in stage III NSCLC.

4.3 Case study analysis: multimodal treatment approaches

One case study analysis involved a patient with locally advanced NSCLC who underwent a multimodal approach combining chemoradiotherapy and immunotherapy. The patient received concurrent chemoradiotherapy followed by durvalumab, an anti-PD-L1 agent, as consolidation therapy. This approach led to a significant reduction in tumor size and prolonged progression-free survival, mirroring the positive outcomes seen in larger clinical trials such as the PACIFIC trial (Spaas and Lievens, 2019). The integration of these therapies provided both local control through radiotherapy and systemic immune responses via immunotherapy, demonstrating the potential of combined treatment strategies (Wang, 2024b).

5 Radiotherapy-Induced Toxicities and Management

5.1 Common side effects of lung cancer radiotherapy

Radiotherapy for lung cancer is associated with several acute and late toxicities. The most common acute toxicities include radiation pneumonitis and esophagitis. Radiation pneumonitis can manifest within weeks to months after radiotherapy, leading to coughing, dyspnea, and fatigue. Esophagitis often occurs during treatment, presenting with pain and difficulty swallowing, and may result in weight loss due to reduced oral intake. Late toxicities include pulmonary fibrosis, which can impair respiratory function long after treatment. Additionally, cardiac toxicities, such as radiation-induced heart disease (RIHD), have been observed, especially with higher doses to the heart during thoracic radiotherapy (Kang et al., 2015; Ming et al., 2016).

5.2 Management of acute and late toxicities

The management of acute toxicities primarily involves symptomatic relief. For radiation pneumonitis, corticosteroids are commonly used to reduce inflammation, while oxygen therapy and bronchodilators can provide respiratory support. Esophagitis is managed with analgesics, acid suppression, and diet modifications to reduce discomfort. Long-term toxicities, such as pulmonary fibrosis, are managed through supportive care including pulmonary rehabilitation and supplemental oxygen. Cardiac toxicity is monitored with regular cardiac function assessments, and management strategies focus on minimizing further damage and addressing cardiovascular risk factors (Baker and Fairchild, 2016; Käsmann et al., 2020).

5.3 Strategies to minimize radiotherapy-related complications

Advancements in radiotherapy techniques, such as intensity-modulated radiotherapy (IMRT) and stereotactic body radiotherapy (SBRT), have helped to reduce the dose delivered to healthy tissues, minimizing toxicities. Using advanced imaging for treatment planning also allows for more precise targeting of the tumor while sparing surrounding organs. To minimize cardiac toxicity, it is essential to limit the dose to the heart by employing techniques such as proton therapy or gating methods to account for tumor motion. Additionally, the use of genetic biomarkers to predict individual susceptibility to radiotherapy-induced toxicities holds promise for personalizing treatment and further reducing complications (Bourbonne et al., 2020; Vojtíšek et al., 2020).

6 Technological Innovations in Radiotherapy Delivery

6.1 Real-time tumor tracking and adaptive radiotherapy

Real-time tumor tracking is a critical innovation in radiotherapy, particularly for lung cancer patients where respiratory motion poses a significant challenge. This technology allows continuous monitoring of tumor movement, adjusting the radiation beam accordingly to ensure accurate targeting of the tumor while minimizing radiation to surrounding healthy tissues. One method involves magnetic resonance-guided radiotherapy (MRgRT), which offers superior soft-tissue contrast for tumor visualization and allows online adaptive radiotherapy based on real-time imaging during treatment. Real-time tumor tracking systems such as U-Net-based models for 4D CT imaging have shown potential to further refine adaptive radiotherapy by improving motion management and tracking (Kronemeijer et al., 2022). These advancements reduce the risk of overexposing healthy tissues to radiation, improving both treatment precision and patient outcomes (Thorwarth and Low, 2021).

6.2 Image-guided radiotherapy (IGRT)

Image-Guided Radiotherapy (IGRT) has revolutionized radiotherapy delivery by integrating imaging techniques to localize the tumor before and during treatment. IGRT improves accuracy by adjusting radiation delivery based on real-time images of the tumor and surrounding anatomy. Recent developments have seen the use of machine learning and artificial intelligence (AI) to enhance IGRT systems by automating image processing tasks such as tumor localization, motion prediction, and adaptive treatment adjustments. These innovations allow for more precise dose delivery and reduce treatment uncertainty, particularly for tumors that move during treatment, such as in lung cancer. AI-based approaches, including deep learning models, have further improved image denoising and real-time image processing, enabling clinicians to make faster and more accurate adjustments during treatment (Mori, 2017).

6.3 Artificial intelligence and machine learning in radiotherapy planning

Artificial intelligence (AI) and machine learning (ML) are rapidly transforming radiotherapy planning, offering significant improvements in treatment precision, efficiency, and adaptability. AI algorithms are being used to automate tasks such as treatment plan optimization, tumor segmentation, and dose prediction, which traditionally relied on manual intervention. AI enhances the accuracy of these processes while reducing time and potential human error. One key development is the integration of AI in magnetic resonance-guided radiotherapy (MRgRT), where machine learning models optimize dose distribution based on daily imaging, enabling highly personalized and adaptive treatments. Additionally, deep learning approaches have been employed to generate synthetic CT images from MR data, streamlining the radiotherapy planning process and further improving the adaptability of treatments. These AI-driven innovations offer the potential for real-time adaptation during treatment, promising better outcomes for patients.

7 Patient Selection and Personalized Radiotherapy

7.1 Biomarkers for predicting radiotherapy response

Biomarkers that predict patient response to radiotherapy are becoming increasingly crucial in personalizing treatment. These biomarkers, such as DNA repair pathway genes, microRNAs, and radiosensitivity indexes, allow for stratifying patients based on their tumor biology. Studies have shown that mutations in DNA repair genes, such as NOTCH1 and CHEK2, are associated with better local control post-radiotherapy, while certain microRNAs (e.g., miR-98-5p and miR-613) can help predict radiotherapy response in lung cancer patients (Tang et al., 2022). Additionally, radiosensitivity indexes have shown promise as predictors in radiotherapy and immunotherapy combinations, allowing for the identification of optimal treatment plans for individual patients.

7.2 Genomic and molecular profiling in treatment planning

Genomic profiling is critical for tailoring radiotherapy treatment. High-throughput sequencing and analysis of genomic alterations, such as those found in the PIK3CA gene, are used to predict tumor response to radiation. For example, patients with PIK3CA mutations in breast cancer have shown lower recurrence rates after radiotherapy, suggesting that this mutation may serve as a protective factor against radiation resistance. Furthermore, molecular profiling of circulating tumor DNA (ctDNA) has emerged as a non-invasive method for monitoring radiotherapy response, offering real-time insights into the dynamic genetic composition of tumors (He et al., 2019).

7.3 Tailoring radiotherapy based on tumor and patient characteristics

Radiotherapy can be tailored by integrating patient-specific characteristics, including tumor genetics and molecular profiles. Personalized approaches involve using biomarkers such as microRNAs and genomic signatures to adjust radiation doses, ensuring optimal therapeutic effects while minimizing side effects. For instance, combining radiomic features with genomics has enabled the identification of patients likely to respond favorably to specific radiotherapy doses and techniques. This approach represents a significant advance in personalized radiotherapy, allowing for more precise and effective treatment plans that take into account individual tumor characteristics and patient variability.

8 Cost-Effectiveness and Accessibility of Advanced Radiotherapy

8.1 Economic considerations in implementing advanced radiotherapy

The implementation of advanced radiotherapy techniques, such as intensity-modulated radiotherapy (IMRT), stereotactic body radiotherapy (SBRT), and carbon-ion radiotherapy (CIRT), has significant economic implications. Studies have shown that these techniques can be cost-effective by improving patient outcomes and reducing long-term treatment costs. For instance, a comparison of SBRT and conventional radiotherapy for early-stage non-small-cell lung cancer (NSCLC) demonstrated that SBRT was more cost-effective, with a favorable incremental cost-effectiveness ratio (ICER) relative to conventional methods, owing to reduced toxicity and fewer hospitalizations (Sun et al., 2022). CIRT, despite its higher upfront costs, has been found to provide excellent long-term survival outcomes and is considered cost-effective in certain patient populations when compared to SBRT (Okazaki et al., 2021).

8.2 Accessibility challenges in low and middle-income countries

Access to advanced radiotherapy techniques is limited in low and middle-income countries (LMICs) due to high costs, lack of infrastructure, and limited trained personnel. In these regions, conventional radiotherapy is often the only available treatment option, while access to advanced modalities such as IMRT or proton therapy remains scarce. Financial barriers and inadequate healthcare infrastructure significantly hinder the widespread adoption of innovative radiotherapy techniques in LMICs. Furthermore, disparities in healthcare funding and limited government support contribute to these challenges (Giuliani and Fiorica, 2021).

8.3 Strategies to improve access to innovative radiotherapy techniques

To improve access to advanced radiotherapy techniques in LMICs, several strategies can be employed. Partnerships between high-income countries and LMICs for knowledge exchange and technology transfer can facilitate the adoption of modern radiotherapy technologies. Additionally, investment in infrastructure, government subsidies, and international support for building radiotherapy centers can help expand access. Expanding training programs to enhance local expertise and the use of cost-sharing models to reduce the financial burden on patients are also critical approaches to making these treatments more accessible (Patrice et al., 2018). Implementing telemedicine and remote planning technologies also holds promise for expanding access to expert radiotherapy care in underserved areas (Hsia et al., 2015).

9 Future Directions in Lung Cancer Radiotherapy

9.1 Emerging radiotherapy technologies: flash radiotherapy and beyond

FLASH radiotherapy is one of the most exciting advancements in the field of radiation oncology. It delivers radiation at ultra-high dose rates, dramatically reducing normal tissue toxicity while maintaining effective tumor control. Preclinical studies on various animal models and early veterinary trials have demonstrated promising results, sparking considerable enthusiasm about the potential of FLASH for clinical use. The unique biological responses observed with FLASH radiotherapy, known as the "FLASH effect," involve reducing radiation-induced damage to healthy tissues while maintaining cancer-killing effects. Ongoing research is focused on understanding the biological mechanisms underlying this phenomenon and on refining the technology for human clinical applications. Additionally, advancements such as proton therapy and adaptive radiotherapy are continuing to evolve, offering enhanced precision in targeting tumors while minimizing damage to adjacent healthy tissues.

9.2 Integrating radiotherapy with novel systemic agents

Combining radiotherapy with novel systemic agents, such as immunotherapy and targeted therapies, is showing promise in improving patient outcomes in lung cancer. Immunotherapies, such as immune checkpoint inhibitors targeting PD-1 and PD-L1, have been combined with radiotherapy to enhance the immune response to tumors. This combination not only provides local control but also stimulates systemic anti-tumor immunity, potentially leading to abscopal effects, where tumors outside the radiation field shrink as well. Similarly, targeted therapies like EGFR inhibitors are being tested in combination with radiotherapy, particularly in patients with specific genetic mutations, offering a more personalized approach to treatment (Simone et al., 2015).

9.3 Research and clinical trials for innovative radiotherapy approaches

Several clinical trials are underway to explore innovative radiotherapy approaches and their integration with systemic therapies. Studies such as the PACIFIC trial have shown the effectiveness of combining durvalumab (an anti-PD-L1 immunotherapy) with chemoradiotherapy in stage III NSCLC, leading to improved survival outcomes. Ongoing research is exploring these combinations further, especially in earlier-stage cancers and in patients with oligometastatic disease. Additionally, clinical trials are investigating the feasibility and safety of FLASH radiotherapy in human patients, aiming to translate preclinical successes into standard clinical practice (Taylor et al., 2022).

10 Concluding Remarks

Radiotherapy has undergone significant innovations in the treatment of lung cancer. Technologies like stereotactic body radiotherapy (SBRT), intensity-modulated radiotherapy (IMRT), and proton therapy have dramatically improved tumor targeting, reduced toxicity, and increased local control rates. Innovations such as FLASH radiotherapy have shown promise in reducing normal tissue damage while maintaining efficacy. Integration with systemic therapies, particularly immunotherapy, has led to improved survival outcomes and potential abscopal effects. Research continues to advance in the personalization of radiotherapy through the use of biomarkers and genomics to predict response and tailor treatments to individual patients.

The adoption of advanced radiotherapy techniques has clear implications for improving patient outcomes, particularly in terms of reducing side effects and improving survival rates. The use of real-time adaptive radiotherapy, combined with advanced imaging and motion tracking, has enabled precise targeting of tumors while sparing healthy tissues. These technological advancements, along with the integration of radiotherapy with immunotherapy, offer enhanced local control and potential systemic anti-tumor effects. Furthermore, the personalized approach to radiotherapy based on genetic and molecular profiling could significantly improve patient selection and tailor treatment regimens to optimize efficacy.

Future research should focus on further understanding the mechanisms of action behind novel radiotherapy techniques such as FLASH radiotherapy and its clinical applications. Additionally, clinical trials should explore the integration of advanced radiotherapy with novel systemic agents, particularly immunotherapy and targeted therapies. Ongoing research is also needed to refine patient selection criteria through biomarkers and genomics to ensure that radiotherapy is tailored to individual patient profiles. Finally, increasing access to these advanced therapies, particularly in low-resource settings, should be a priority for future clinical practice.

Acknowledgment

I would like to express my sincere gratitude to the anonymous reviewers for their valuable suggestions on this study.

Conflict of Interest Disclosure

The author affirms that this research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest.

References

Bae B.K., Yang K., Noh J., Pyo H., and Ahn Y., 2022, Clinical outcomes following proton and photon stereotactic body radiation therapy for early-stage lung cancer, Cancers, 14(17): 4152.

https://doi.org/10.3390/cancers14174152

PMID: 36077688 PMCID: PMC9454659

Baker S., and Fairchild A., 2016, Radiation-induced esophagitis in lung cancer, Lung Cancer: Targets and Therapy, 7: 119-127.

https://doi.org/10.2147/LCTT.S96443

PMID: 28210168 PMCID: PMC5310706

Ball D., Mai G.T., Vinod S., Babington S., Ruben J., Kron T., Chesson B., Herschtal A., Vanevski M., Rezo A., Elder C., Skala M., Wirth A., Wheeler G., Lim A., Shaw M., Schofield P., Irving L., and Solomon B., 2019, Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial, The Lancet Oncology, 20: 494-503.

https://doi.org/10.1016/S1470-2045(18)30896-9

Bhalla N., Brooker R., and Brada M., 2018, Combining immunotherapy and radiotherapy in lung cancer, Journal of Thoracic Disease, 10(Suppl 13): 1447-1460.

https://doi.org/10.21037/jtd.2018.05.107

PMID: 29951296 PMCID: PMC5994496

Bourbonne V., Da-Ano R., Jaouen V., Lucia F., Dissaux G., Bert J., Pradier O., Visvikis D., and Hatt M., 2020, Radiomics analysis of 3D dose distributions to predict toxicity of radiotherapy for lung cancer, Radiotherapy and Oncology, 155: 144-150.

https://doi.org/10.1016/j.radonc.2020.10.040

Cassidy R.J., 2017, SBRT found safe, effective in elderly with inoperable early-stage NSCLC, Oncology Times, 39(8): 36.

https://doi.org/10.1097/01.cot.0000516149.89807.52

Chun S.G., Hu C., Choy H., Komaki R., Timmerman R.D., Schild S.E., and Bradley J.D., 2017, Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer, Journal of Clinical Oncology, 35(1): 56-62.

https://doi.org/10.1200/JCO.2016.69.1378

PMID: 28034064 PMCID: PMC5455690

Diwanji T., Mohindra P., Vyfhuis M., Snider J., Kalavagunta C., Mossahebi S., Yu J., Feigenberg S., and Badiyan S., 2017, Advances in radiotherapy techniques and delivery for non-small cell lung cancer: benefits of intensity-modulated radiation therapy, proton therapy, and stereotactic body radiation therapy, Translational Lung Cancer Research, 6(2): 131-147.

https://doi.org/10.21037/tlcr.2017.04.04

PMID: 28529896 PMCID: PMC5420540

Fiorino C., Guckenberger M., Schwarz M., Heide U., and Heijmen B., 2020, Technology-driven research for radiotherapy innovation, Molecular Oncology, 14: 1500-1513.

https://doi.org/10.1002/1878-0261.12659

PMID: 32124546 PMCID: PMC7332218

Giuliani J., and Fiorica F., 2021, Cost-effectiveness of immune checkpoint inhibitors and radiotherapy in advanced non-small cell lung cancer, Journal of Oncology Pharmacy Practice, 27(6): 2004-2006.

https://doi.org/10.1177/10781552211038925

Harada H., and Murayama S., 2017, Proton beam therapy in non-small cell lung cancer: state of the art, Lung Cancer: Targets and Therapy, 8: 141-145.

https://doi.org/10.2147/LCTT.S117647

PMID: 28883747 PMCID: PMC5574682

He K., Zhang S., Shao L., Yin J.C., Wu X., Shao Y., Yuan S., and Yu J., 2019, Developing more sensitive genomic approaches to detect radioresponse in precision radiation oncology: from tissue DNA analysis to circulating tumor DNA, Cancer Letters, 472: 108-118.

https://doi.org/10.1016/j.canlet.2019.12.004

Hsia T., Tu C., Fang H., Liang J., Li C., and Chien C., 2015, Cost and effectiveness of image-guided radiotherapy for non-operated localized lung cancer: a population-based propensity score-matched analysis, Journal of Thoracic Disease, 7(9): 1643-1649.

https://doi.org/10.3978/j.issn.2072-1439.2015.09.36

PMID: 26543613 PMCID: PMC4598523

Kang K.H., Okoye C., Patel R., Siva S., Biswas T., Ellis R., Yao M., Machtay M., and Lo S., 2015, Complications from stereotactic body radiotherapy for lung cancer, Cancers, 7(2): 981-1004.

https://doi.org/10.3390/cancers7020820

PMID: 26083933 PMCID: PMC4491695

Käsmann L., Dietrich A., Staab-Weijnitz C., Manapov F., Behr J., Rimner A., Jeremic B., Senan S., de Ruysscher D., Lauber K., and Belka C., 2020, Radiation-induced lung toxicity - cellular and molecular mechanisms of pathogenesis, management, and literature review, Radiation Oncology, 15(1): 214.

https://doi.org/10.1186/s13014-020-01654-9

PMID: 32912295 PMCID: PMC7488099

Kreinbrink P., Blumenfeld P., Tolekidis G., Sen N., Sher D., and Marwaha G., 2017, Lung stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer in the very elderly (≥80 years old): extremely safe and effective, Journal of Geriatric Oncology, 8(5): 351-355.

https://doi.org/10.1016/j.jgo.2017.07.002

Kronemeijer P., Gavves E., Sonke J., and Teuwen J., 2022, Tumor tracking in 4D CT images for adaptive radiotherapy, Proceedings of SPIE Medical Imaging, 12032: 2612954.

https://doi.org/10.1117/12.2612954

Ming X., Feng Y., Yang C., Wang W., Wang P., and Deng J., 2016, Radiation-induced heart disease in lung cancer radiotherapy, Medicine, 95(41): e5051.

https://doi.org/10.1097/MD.0000000000005051

PMID: 27741117 PMCID: PMC5072944

Mori S., 2017, Deep architecture neural network-based real-time image processing for image-guided radiotherapy, Physica Medica, 40: 79-87.

https://doi.org/10.1016/j.ejmp.2017.07.013

Muto M., Spagnuolo A., and Gridelli C., 2020, The role of combined radiotherapy and immunotherapy in locally advanced non-small cell lung cancer, Archives of Clinical and Biomedical Research, 4(6): 794-816.

https://doi.org/10.26502/acbr.50170144

Okazaki S., Shibuya K., Takura T., Miyasaka Y., Kawamura H., and Ohno T., 2021, Cost-effectiveness of carbon-ion radiotherapy versus stereotactic body radiotherapy for non-small-cell lung cancer, Cancer Science, 113(2): 674-683.

https://doi.org/10.1111/cas.15216

PMID: 34820994 PMCID: PMC8819294

Patrice G., Lester-Coll N., Yu J.B., Amdahl J., and Delea T., 2018, Cost-effectiveness of thoracic radiation therapy for extensive-stage small cell lung cancer using evidence from the chest radiotherapy extensive-stage small cell lung cancer trial (CREST), International Journal of Radiation Oncology, Biology, Physics, 100(1): 97-106.

https://doi.org/10.1016/j.ijrobp.2017.08.041

Sacco P., Maione P., Guida C., and Gridelli C., 2017, The combination of new immunotherapy and radiotherapy: a new potential treatment for locally advanced non-small cell lung cancer, Current Clinical Pharmacology, 12(1): 4-10.

https://doi.org/10.2174/1574884711666161201123439

Shioyama Y., Suefuji H., Shinoto M., Terashima K., and Toyama S., 2017, Carbon-ion radiotherapy for lung cancer: current status and future directions, J-Stage, 57: 723-732.

https://doi.org/10.2482/HAIGAN.57.723

Simone C., Burri S., and Heinzerling J., 2015, Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies, Translational Lung Cancer Research, 4(5): 545-552.

https://doi.org/10.3978/j.issn.2218-6751.2015.10.05

PMID: 26629423 PMCID: PMC4630515

Spaas M., and Lievens Y., 2019, Is the combination of immunotherapy and radiotherapy in non-small cell lung cancer a feasible and effective approach?, Frontiers in Medicine, 6: 244.

https://doi.org/10.3389/fmed.2019.00244

PMID: 31788476 PMCID: PMC6853895

Sun H., Jin C., Wang H., Hu S., Chen Y., and Wang H., 2022, Cost-effectiveness of stereotactic body radiotherapy in the treatment of non-small-cell lung cancer (NSCLC): a systematic review, Expert Review of Pharmacoeconomics and Outcomes Research, 22(6): 723-734.

https://doi.org/10.1080/14737167.2022.2050217

PMID: 35249432

Tang C., Qi J., Wu Y., Luo L., Wang Y., Wu Y., and Shi X., 2022, Improving the prediction for the response to radiotherapy of clinical tumor samples by using combinatorial model of MicroRNA expression, Frontiers in Genetics, 13: 1069112.

https://doi.org/10.3389/fgene.2022.1069112

PMID: 36482894 PMCID: PMC9723130

Taylor P., Moran J., Jaffray D., and Buchsbaum J., 2022, A roadmap to clinical trials for FLASH, Medical Physics, 49: 4099-4108.

https://doi.org/10.1002/mp.15623

PMID: 35366339 PMCID: PMC9321729

Thorwarth D., and Low D., 2021, Technical challenges of real-time adaptive MR-guided radiotherapy, Frontiers in Oncology, 11: 634507.

https://doi.org/10.3389/fonc.2021.634507

PMID: 33763369 PMCID: PMC7982516

Vinod S., and Hau E., 2020, Radiotherapy treatment for lung cancer: current status and future directions, Respirology, 25: 61-71.

https://doi.org/10.1111/resp.13870

PMID: 32516852

Vojtíšek R., 2020, Cardiac toxicity of lung cancer radiotherapy, Reports of Practical Oncology and Radiotherapy, 25(1): 13-19.

https://doi.org/10.1016/j.rpor.2019.10.007

PMID: 31762693 PMCID: PMC6864155

Wang T., 2024a, The application prospects of immunomodulators in cancer treatment, Cancer Genetics and Epigenetics, 12(1): 1-7.

https://doi.org/10.5376/cge.2024.12.0001

Wang W., 2024b, The application and challenges of emerging technologies in early diagnosis and screening of gastric cancer: from molecular markers to imaging advances, Cancer Genetics and Epigenetics, 12(1): 37-46.

https://doi.org/10.5376/cge.2024.12.0005